Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDE2REPAIR phase II olaparib + durvalumab + tremelimumab study in homologous recombination repair-mutated solid cancers
2018-002971-17Phase 2Active
- Sponsor
- Centre Georges-François Leclerc
- Start
- May 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib, durvalumab and tremelimumab in Non-hematologic malignancy, breast cancer, prostate cancer (PCa) and 3 more, sponsored by Centre Georges-François Leclerc. Primary endpoints: 6-month progression-free survival rate, 12-month progression-free survival rate and 1 more. Started May 2019; status: active.
02
Drugs
olaparibdurvalumabtremelimumab
03
Conditions
Non-hematologic malignancybreast cancerprostate cancer (PCa)Non-small cell lung cancer adenocarcinoma (NSCLC)ovarian cancer
Beyond the preview
Go deeper on 2018-002971-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002971-17.